Pluri (PLUR) to Announce Quarterly Earnings on Wednesday

Pluri (NASDAQ:PLUR) is expected to be releasing its results after the market closes on Wednesday, September 23rd. Analysts expect the company to post earnings of ($0.66) per share and revenue of $0.6550 million for the quarter.

Pluri (NASDAQ:PLUR) last issued its quarterly earnings data on Thursday, September 10th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The company had revenue of $0.34 million for the quarter, compared to analysts’ expectations of $0.66 million.

Pluri Trading Down 0.9%

Shares of NASDAQ PLUR opened at $1.07 on Tuesday. The firm has a fifty day simple moving average of $1.56 and a two-hundred day simple moving average of $2.40. Pluri has a 12 month low of $1.01 and a 12 month high of $4.87. The firm has a market capitalization of $13.21 million, a PE ratio of -0.44 and a beta of 0.68.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Pluri presently has an average rating of “Sell”.

About Pluri

Pluri Ltd. is an Israel-based biotechnology company that develops cell-based products using its proprietary three-dimensional cell expansion technology. The platform is designed to produce large quantities of potentially therapeutic and commercial cells while maintaining consistent quality and scalability.

The company’s research and development activities have included placenta-derived, off-the-shelf cell therapies, historically marketed under the PLX platform. These programs have targeted areas such as regenerative medicine, inflammation, cancer, orthopedic conditions and other medical needs.